FAMOTIDINE

Post-LOE

famotidine

ANDAORALTABLET
Approved
Mar 2024
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
19

Mechanism of Action

histamine-2 (H2) receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.

Clinical Trials (5)

NCT07171619Phase 1Recruiting

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

Started Sep 2025
24 enrolled
Healthy
NCT05866627Phase 1Recruiting

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

Started Jul 2023
76 enrolled
Healthy Volunteers
NCT04941755Phase 1Completed

A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Started Jun 2021
22 enrolled
Healthy Participants
NCT04470778Phase 1Completed

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Started Jul 2020
35 enrolled
Healthy Participants
NCT04209699Phase 1Completed

A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers

Started Dec 2019
18 enrolled
Healthy Participants